$LFCR
LIFECORE BIOMEDICAL, INC. \DE\ Stock $lfcr

$lfcr Overview Financials Valuation SEC Filings Company Website

2023 Q2 Form 10-Q Financial Statement

#000100528623000095 Filed on June 02, 2023

Income Statement

Concept	2023 Q2	2023 Q1
Revenue	$31.55M	$27.60M
YoY Change	-33.77%	-48.0%
Cost Of Revenue	$23.16M	$21.62M
YoY Change	-36.22%	-44.81%
Gross Profit	$8.391M	$5.978M
YoY Change	-30.72%	-56.98%
Gross Profit Margin	26.6%	21.66%
Selling, General & Admin	$11.69M	$10.97M
YoY Change	-38.23%	12.82%
% of Gross Profit	139.27%	183.54%
Research & Development	$2.116M	$1.964M
YoY Change	2.92%	-4.47%
% of Gross Profit	25.22%	32.85%
Depreciation & Amortization	$3.118M	$3.150M
YoY Change	-8.19%	-10.74%
% of Gross Profit	37.16%	52.69%
Operating Expenses	$13.80M	$15.68M
YoY Change	-34.2%	-11.16%
Operating Profit	-$5.411M	-$9.699M
YoY Change	-38.96%	158.57%
Interest Expense	-$4.454M	$5.818M
YoY Change	28.54%	41.73%
% of Operating Profit
Other Income/Expense, Net	-$318.0K	$34.00K
YoY Change	-105.47%	-92.51%
Pretax Income	-$33.57M	-$15.39M
YoY Change	-8.26%	108.49%
Income Tax	$223.0K	$70.00K
% Of Pretax Income
Net Earnings	-$36.13M	-$40.19M
YoY Change	-1.45%	212.78%
Net Earnings / Revenue	-114.53%	-145.62%
Basic Earnings Per Share	-$1.32	-$1.33
Diluted Earnings Per Share	-$1.19	-$1.33
COMMON SHARES
Basic Shares Outstanding	30.32M shares	30.32M shares
Diluted Shares Outstanding		30.30M shares

Balance Sheet

Concept	2023 Q2	2023 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments	$19.09M	$3.000M
YoY Change	1061.96%	61.81%
Cash & Equivalents	$19.09M	$2.950M
Short-Term Investments
Other Short-Term Assets	$5.078M	$4.400M
YoY Change	-27.99%	-36.45%
Inventory	$45.38M	$48.70M
Prepaid Expenses
Receivables	$29.71M	$32.37M
Other Receivables	$0.00	$0.00
Total Short-Term Assets	$99.26M	$88.44M
YoY Change	-19.76%	-33.02%
LONG-TERM ASSETS
Property, Plant & Equipment	$134.6M	$120.8M
YoY Change	3.22%	-1.96%
Goodwill	$13.90M	$13.88M
YoY Change	0.14%	-59.07%
Intangibles	$4.200M	$4.400M
YoY Change	-50.0%	-74.27%
Long-Term Investments
YoY Change
Other Assets	$3.215M	$2.710M
YoY Change	7.1%	-11.09%
Total Long-Term Assets	$155.9M	$147.7M
YoY Change	-9.08%	-23.68%
TOTAL ASSETS
Total Short-Term Assets	$99.26M	$88.44M
Total Long-Term Assets	$155.9M	$147.7M
Total Assets	$255.2M	$236.2M
YoY Change	-13.56%	-27.47%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$22.14M	$14.76M
YoY Change	40.13%	-26.24%
Accrued Expenses	$12.09M	$20.20M
YoY Change	-35.09%	-29.21%
Deferred Revenue	$4.100M	$2.711M
YoY Change	346.14%	67.97%
Short-Term Debt	$0.00	$0.00
YoY Change	-100.0%	-100.0%
Long-Term Debt Due	$488.0K	$0.00
YoY Change	-18.53%
Total Short-Term Liabilities	$38.78M	$37.67M
YoY Change	-51.06%	-58.17%
LONG-TERM LIABILITIES
Long-Term Debt	$101.3M	$98.96M
YoY Change	3.79%	24.33%
Other Long-Term Liabilities	$77.32M	$203.0K
YoY Change	40596.32%	-62.68%
Total Long-Term Liabilities	$178.6M	$99.17M
YoY Change	82.67%	23.74%
TOTAL LIABILITIES
Total Short-Term Liabilities	$38.78M	$37.67M
Total Long-Term Liabilities	$178.6M	$99.17M
Total Liabilities	$217.7M	$163.4M
YoY Change	16.31%	-9.96%
SHAREHOLDERS EQUITY
Retained Earnings	-$178.5M	-$140.1M
YoY Change	203.37%	531.38%
Common Stock	$30.00K	$30.00K
YoY Change	0.0%	3.45%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$37.40M	$34.21M
YoY Change
Total Liabilities & Shareholders Equity	$255.2M	$236.2M
YoY Change	-13.56%	-27.47%

Cashflow Statement

Concept	2023 Q2	2023 Q1
OPERATING ACTIVITIES
Net Income	-$36.13M	-$40.19M
YoY Change	-1.45%	212.78%
Depreciation, Depletion And Amortization	$3.118M	$3.150M
YoY Change	-8.19%	-10.74%
Cash From Operating Activities	-$17.29M	-$12.69M
YoY Change	-48122.22%	-36.96%
INVESTING ACTIVITIES
Capital Expenditures	$8.443M	$6.140M
YoY Change	-187.99%	-211.05%
Acquisitions
YoY Change
Other Investing Activities	$940.0K	$12.53M
YoY Change	-109.6%	-82.96%
Cash From Investing Activities	-$7.503M	$6.400M
YoY Change	-61.3%	-90.59%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	40.93M	2.410M
YoY Change	113.82%	-105.12%
NET CHANGE
Cash From Operating Activities	-17.29M	-12.69M
Cash From Investing Activities	-7.503M	6.400M
Cash From Financing Activities	40.93M	2.410M
Net Change In Cash	16.14M	-3.880M
YoY Change	-7748.34%	-608.52%
FREE CASH FLOW
Cash From Operating Activities	-$17.29M	-$12.69M
Capital Expenditures	$8.443M	$6.140M
Free Cash Flow	-$25.73M	-$18.83M
YoY Change	-367.17%	28.97%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
	dei	Entity Central Index Key EntityCentralIndexKey	0001005286
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--05-28
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2023
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q3
	dei	Amendment Flag AmendmentFlag	false
	us-gaap	Revenue From Contract With Customer Product And Service Extensible List RevenueFromContractWithCustomerProductAndServiceExtensibleList	http://fasb.org/us-gaap/2022#ProductMember
CY2022Q1	us-gaap	Revenue From Contract With Customer Product And Service Extensible List RevenueFromContractWithCustomerProductAndServiceExtensibleList	http://fasb.org/us-gaap/2022#ProductMember
CY2023Q1	us-gaap	Revenue From Contract With Customer Product And Service Extensible List RevenueFromContractWithCustomerProductAndServiceExtensibleList	http://fasb.org/us-gaap/2022#ProductMember
	us-gaap	Revenue From Contract With Customer Product And Service Extensible List RevenueFromContractWithCustomerProductAndServiceExtensibleList	http://fasb.org/us-gaap/2022#ProductMember
	us-gaap	Type Of Cost Good Or Service Extensible List TypeOfCostGoodOrServiceExtensibleList	http://fasb.org/us-gaap/2022#ProductMember
CY2022Q1	us-gaap	Type Of Cost Good Or Service Extensible List TypeOfCostGoodOrServiceExtensibleList	http://fasb.org/us-gaap/2022#ProductMember
CY2023Q1	us-gaap	Type Of Cost Good Or Service Extensible List TypeOfCostGoodOrServiceExtensibleList	http://fasb.org/us-gaap/2022#ProductMember
	us-gaap	Type Of Cost Good Or Service Extensible List TypeOfCostGoodOrServiceExtensibleList	http://fasb.org/us-gaap/2022#ProductMember
	dei	Document Type DocumentType	10-Q
	dei	Document Quarterly Report DocumentQuarterlyReport	true
	dei	Document Period End Date DocumentPeriodEndDate	2023-02-26
	dei	Document Transition Report DocumentTransitionReport	false
	dei	Entity File Number EntityFileNumber	000-27446
	dei	Entity Registrant Name EntityRegistrantName	LIFECORE BIOMEDICAL, INC.
	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	94-3025618
	dei	Entity Address Address Line1 EntityAddressAddressLine1	3515 Lyman Boulevard
	dei	Entity Address City Or Town EntityAddressCityOrTown	Chaska,
	dei	Entity Address State Or Province EntityAddressStateOrProvince	MN
	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	55318
	dei	City Area Code CityAreaCode	952
	dei	Local Phone Number LocalPhoneNumber	368-4300
	dei	Security12b Title Security12bTitle	Common stock, par value $0.001 per share
	dei	Trading Symbol TradingSymbol	LFCR
	dei	Security Exchange Name SecurityExchangeName	NASDAQ
	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
	dei	Entity Filer Category EntityFilerCategory	Accelerated Filer
	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
	dei	Entity Small Business EntitySmallBusiness	false
	dei	Entity Shell Company EntityShellCompany	false
CY2023Q2	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	30322169	shares
CY2023Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	2950000	usd
CY2022Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	991000	usd
CY2023Q1	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	32371000	usd
CY2022Q2	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	40094000	usd
CY2023Q1	us-gaap	Inventory Net InventoryNet	48696000	usd
CY2022Q2	us-gaap	Inventory Net InventoryNet	44300000	usd
CY2023Q1	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	4422000	usd
CY2022Q2	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	5183000	usd
CY2023Q1	us-gaap	Assets Of Disposal Group Including Discontinued Operation Current AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent	0	usd
CY2022Q2	us-gaap	Assets Of Disposal Group Including Discontinued Operation Current AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent	33144000	usd
CY2023Q1	us-gaap	Assets Current AssetsCurrent	88439000	usd
CY2022Q2	us-gaap	Assets Current AssetsCurrent	123712000	usd
CY2023Q1	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	120799000	usd
CY2022Q2	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	115031000	usd
CY2023Q1	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	5924000	usd
CY2022Q2	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	6519000	usd
CY2023Q1	us-gaap	Goodwill Goodwill	13881000	usd
CY2022Q2	us-gaap	Goodwill Goodwill	13881000	usd
CY2023Q1	us-gaap	Indefinite Lived Trademarks IndefiniteLivedTrademarks	4400000	usd
CY2022Q2	us-gaap	Indefinite Lived Trademarks IndefiniteLivedTrademarks	4700000	usd
CY2023Q1	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	2710000	usd
CY2022Q2	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	2900000	usd
CY2023Q1	us-gaap	Disposal Group Including Discontinued Operation Other Noncurrent Assets DisposalGroupIncludingDiscontinuedOperationOtherNoncurrentAssets	0	usd
CY2022Q2	us-gaap	Disposal Group Including Discontinued Operation Other Noncurrent Assets DisposalGroupIncludingDiscontinuedOperationOtherNoncurrentAssets	11063000	usd
CY2023Q1	us-gaap	Assets Assets	236153000	usd
CY2022Q2	us-gaap	Assets Assets	277806000	usd
CY2023Q1	us-gaap	Accounts Payable Current AccountsPayableCurrent	14762000	usd
CY2022Q2	us-gaap	Accounts Payable Current AccountsPayableCurrent	12988000	usd
CY2023Q1	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	6733000	usd
CY2022Q2	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	8941000	usd
CY2023Q1	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	12012000	usd
CY2022Q2	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	6847000	usd
CY2023Q1	lfcr	Operating And Finance Lease Liability Current OperatingAndFinanceLeaseLiabilityCurrent	1455000	usd
CY2022Q2	lfcr	Operating And Finance Lease Liability Current OperatingAndFinanceLeaseLiabilityCurrent	4592000	usd
CY2023Q1	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	2711000	usd
CY2022Q2	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	919000	usd
CY2023Q1	us-gaap	Lines Of Credit Current LinesOfCreditCurrent	0	usd
CY2022Q2	us-gaap	Lines Of Credit Current LinesOfCreditCurrent	40000000	usd
CY2023Q1	us-gaap	Long Term Debt Current LongTermDebtCurrent	0	usd
CY2022Q2	us-gaap	Long Term Debt Current LongTermDebtCurrent	98178000	usd
CY2023Q1	us-gaap	Liabilities Of Disposal Group Including Discontinued Operation Current LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent	0	usd
CY2022Q2	us-gaap	Liabilities Of Disposal Group Including Discontinued Operation Current LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent	4345000	usd
CY2023Q1	us-gaap	Liabilities Current LiabilitiesCurrent	37673000	usd
CY2022Q2	us-gaap	Liabilities Current LiabilitiesCurrent	176810000	usd
CY2023Q1	us-gaap	Line Of Credit LineOfCredit	16000000	usd
CY2022Q2	us-gaap	Line Of Credit LineOfCredit	0	usd
CY2023Q1	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	98964000	usd
CY2022Q2	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	0	usd
CY2023Q1	lfcr	Operating And Finance Lease Liability Noncurrent OperatingAndFinanceLeaseLiabilityNoncurrent	10516000	usd
CY2022Q2	lfcr	Operating And Finance Lease Liability Noncurrent OperatingAndFinanceLeaseLiabilityNoncurrent	8356000	usd
CY2023Q1	us-gaap	Deferred Income Tax Liabilities Net DeferredIncomeTaxLiabilitiesNet	80000	usd
CY2022Q2	us-gaap	Deferred Income Tax Liabilities Net DeferredIncomeTaxLiabilitiesNet	126000	usd
CY2023Q1	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	203000	usd
CY2022Q2	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	190000	usd
CY2023Q1	us-gaap	Liabilities Of Disposal Group Including Discontinued Operation Noncurrent LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationNoncurrent	0	usd
CY2022Q2	us-gaap	Liabilities Of Disposal Group Including Discontinued Operation Noncurrent LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationNoncurrent	1627000	usd
CY2023Q1	us-gaap	Liabilities Liabilities	163436000	usd
CY2022Q2	us-gaap	Liabilities Liabilities	187109000	usd
CY2023Q1	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2022Q2	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2022Q2	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	2000000	shares
CY2023Q1	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	2000000	shares
CY2023Q1	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	39000	shares
CY2023Q1	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	39000	shares
CY2022Q2	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2022Q2	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2023Q1	us-gaap	Temporary Equity Carrying Amount Attributable To Parent TemporaryEquityCarryingAmountAttributableToParent	38510000	usd
CY2022Q2	us-gaap	Temporary Equity Carrying Amount Attributable To Parent TemporaryEquityCarryingAmountAttributableToParent	0	usd
CY2022Q2	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2023Q1	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2023Q1	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	50000000	shares
CY2022Q2	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	50000000	shares
CY2023Q1	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	30319000	shares
CY2023Q1	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	30319000	shares
CY2022Q2	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	29513000	shares
CY2022Q2	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	29513000	shares
CY2023Q1	us-gaap	Common Stock Value CommonStockValue	30000	usd
CY2022Q2	us-gaap	Common Stock Value CommonStockValue	30000	usd
CY2023Q1	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	174268000	usd
CY2022Q2	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	167352000	usd
CY2023Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-140091000	usd
CY2022Q2	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-76099000	usd
CY2023Q1	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	0	usd
CY2022Q2	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-586000	usd
CY2023Q1	us-gaap	Stockholders Equity StockholdersEquity	34207000	usd
CY2022Q2	us-gaap	Stockholders Equity StockholdersEquity	90697000	usd
CY2023Q1	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	236153000	usd
CY2022Q2	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	277806000	usd
CY2023Q1	us-gaap	Revenue From Contract With Customer Including Assessed Tax RevenueFromContractWithCustomerIncludingAssessedTax	27600000	usd
CY2022Q1	us-gaap	Revenue From Contract With Customer Including Assessed Tax RevenueFromContractWithCustomerIncludingAssessedTax	37399000	usd
	us-gaap	Revenue From Contract With Customer Including Assessed Tax RevenueFromContractWithCustomerIncludingAssessedTax	77748000	usd
	us-gaap	Revenue From Contract With Customer Including Assessed Tax RevenueFromContractWithCustomerIncludingAssessedTax	90140000	usd
CY2023Q1	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	21622000	usd
CY2022Q1	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	24533000	usd
	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	58178000	usd
	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	58507000	usd
CY2023Q1	us-gaap	Gross Profit GrossProfit	5978000	usd
CY2022Q1	us-gaap	Gross Profit GrossProfit	12866000	usd
	us-gaap	Gross Profit GrossProfit	19570000	usd
	us-gaap	Gross Profit GrossProfit	31633000	usd
CY2023Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	1964000	usd
CY2022Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	2000000	usd
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	6128000	usd
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	5722000	usd
CY2023Q1	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	10972000	usd
CY2022Q1	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	14163000	usd
	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	31201000	usd
	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	27659000	usd
CY2023Q1	us-gaap	Impairment Of Intangible Assets Excluding Goodwill ImpairmentOfIntangibleAssetsExcludingGoodwill	0	usd
CY2022Q1	us-gaap	Impairment Of Intangible Assets Excluding Goodwill ImpairmentOfIntangibleAssetsExcludingGoodwill	0	usd
	us-gaap	Impairment Of Intangible Assets Excluding Goodwill ImpairmentOfIntangibleAssetsExcludingGoodwill	300000	usd
	us-gaap	Impairment Of Intangible Assets Excluding Goodwill ImpairmentOfIntangibleAssetsExcludingGoodwill	0	usd
CY2023Q1	us-gaap	Gain Loss On Sale Of Business GainLossOnSaleOfBusiness	0	usd
CY2022Q1	us-gaap	Gain Loss On Sale Of Business GainLossOnSaleOfBusiness	0	usd
	us-gaap	Gain Loss On Sale Of Business GainLossOnSaleOfBusiness	2108000	usd
	us-gaap	Gain Loss On Sale Of Business GainLossOnSaleOfBusiness	0	usd
CY2023Q1	us-gaap	Restructuring Charges RestructuringCharges	2741000	usd
CY2022Q1	us-gaap	Restructuring Charges RestructuringCharges	5270000	usd
	us-gaap	Restructuring Charges RestructuringCharges	4611000	usd
	us-gaap	Restructuring Charges RestructuringCharges	7530000	usd
CY2023Q1	us-gaap	Operating Expenses OperatingExpenses	15677000	usd
CY2022Q1	us-gaap	Operating Expenses OperatingExpenses	21433000	usd
	us-gaap	Operating Expenses OperatingExpenses	40132000	usd
	us-gaap	Operating Expenses OperatingExpenses	40911000	usd
CY2023Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-9699000	usd
CY2022Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-8567000	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	-20562000	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	-9278000	usd
CY2023Q1	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-15391000	usd
CY2022Q1	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-6725000	usd
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-34635000	usd
CY2023Q1	us-gaap	Investment Income Interest InvestmentIncomeInterest	22000	usd
CY2022Q1	us-gaap	Investment Income Interest InvestmentIncomeInterest	20000	usd
	us-gaap	Investment Income Interest InvestmentIncomeInterest	53000	usd
	us-gaap	Investment Income Interest InvestmentIncomeInterest	66000	usd
CY2023Q1	us-gaap	Interest Expense InterestExpense	5818000	usd
CY2022Q1	us-gaap	Interest Expense InterestExpense	4105000	usd
	us-gaap	Interest Expense InterestExpense	13715000	usd
	us-gaap	Interest Expense InterestExpense	13877000	usd
CY2023Q1	lfcr	Transition Services Income TransitionServicesIncome	70000	usd
CY2022Q1	lfcr	Transition Services Income TransitionServicesIncome	5473000	usd
	lfcr	Transition Services Income TransitionServicesIncome	70000	usd
	lfcr	Transition Services Income TransitionServicesIncome	5473000	usd
CY2023Q1	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	34000	usd
CY2022Q1	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	454000	usd
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-481000	usd
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	642000	usd
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-16974000	usd
CY2023Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	70000	usd
CY2022Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-87000	usd
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	78000	usd
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-5591000	usd
CY2023Q1	us-gaap	Income Loss From Continuing Operations Including Portion Attributable To Noncontrolling Interest IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest	-15461000	usd
CY2022Q1	us-gaap	Income Loss From Continuing Operations Including Portion Attributable To Noncontrolling Interest IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest	-6638000	usd
	us-gaap	Income Loss From Continuing Operations Including Portion Attributable To Noncontrolling Interest IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest	-34713000	usd
	us-gaap	Income Loss From Continuing Operations Including Portion Attributable To Noncontrolling Interest IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest	-11383000	usd
CY2023Q1	us-gaap	Discontinued Operation Income Loss From Discontinued Operation Before Income Tax DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax	-24731000	usd
CY2022Q1	us-gaap	Discontinued Operation Income Loss From Discontinued Operation Before Income Tax DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax	-6859000	usd
	us-gaap	Discontinued Operation Income Loss From Discontinued Operation Before Income Tax DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax	-29279000	usd
	us-gaap	Discontinued Operation Income Loss From Discontinued Operation Before Income Tax DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax	-49576000	usd
CY2023Q1	us-gaap	Discontinued Operation Tax Effect Of Discontinued Operation DiscontinuedOperationTaxEffectOfDiscontinuedOperation	0	usd
CY2022Q1	us-gaap	Discontinued Operation Tax Effect Of Discontinued Operation DiscontinuedOperationTaxEffectOfDiscontinuedOperation	-411000	usd
	us-gaap	Discontinued Operation Tax Effect Of Discontinued Operation DiscontinuedOperationTaxEffectOfDiscontinuedOperation	0	usd
	us-gaap	Discontinued Operation Tax Effect Of Discontinued Operation DiscontinuedOperationTaxEffectOfDiscontinuedOperation	157000	usd
CY2023Q1	us-gaap	Income Loss From Discontinued Operations Net Of Tax IncomeLossFromDiscontinuedOperationsNetOfTax	-24731000	usd
CY2022Q1	us-gaap	Income Loss From Discontinued Operations Net Of Tax IncomeLossFromDiscontinuedOperationsNetOfTax	-6448000	usd
	us-gaap	Income Loss From Discontinued Operations Net Of Tax IncomeLossFromDiscontinuedOperationsNetOfTax	-29279000	usd
	us-gaap	Income Loss From Discontinued Operations Net Of Tax IncomeLossFromDiscontinuedOperationsNetOfTax	-49733000	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	-40192000	usd
CY2022Q1	us-gaap	Net Income Loss NetIncomeLoss	-13086000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-63992000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-61116000	usd
CY2023Q1	us-gaap	Income Loss From Continuing Operations Per Basic Share IncomeLossFromContinuingOperationsPerBasicShare	-0.51
CY2022Q1	us-gaap	Income Loss From Continuing Operations Per Basic Share IncomeLossFromContinuingOperationsPerBasicShare	-0.23
	us-gaap	Income Loss From Continuing Operations Per Basic Share IncomeLossFromContinuingOperationsPerBasicShare	-1.16
	us-gaap	Income Loss From Continuing Operations Per Basic Share IncomeLossFromContinuingOperationsPerBasicShare	-0.39
CY2023Q1	us-gaap	Income Loss From Discontinued Operations Net Of Tax Per Basic Share IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare	-0.82
CY2022Q1	us-gaap	Income Loss From Discontinued Operations Net Of Tax Per Basic Share IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare	-0.22
	us-gaap	Income Loss From Discontinued Operations Net Of Tax Per Basic Share IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare	-0.98
CY2023Q1	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	0	usd
	us-gaap	Income Loss From Discontinued Operations Net Of Tax Per Basic Share IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare	-1.68
CY2023Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-1.33
CY2022Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.45
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-2.14
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-2.07
CY2023Q1	us-gaap	Income Loss From Continuing Operations Per Diluted Share IncomeLossFromContinuingOperationsPerDilutedShare	-0.51
CY2022Q1	us-gaap	Income Loss From Continuing Operations Per Diluted Share IncomeLossFromContinuingOperationsPerDilutedShare	-0.23
	us-gaap	Income Loss From Continuing Operations Per Diluted Share IncomeLossFromContinuingOperationsPerDilutedShare	-1.16
	us-gaap	Income Loss From Continuing Operations Per Diluted Share IncomeLossFromContinuingOperationsPerDilutedShare	-0.39
CY2023Q1	us-gaap	Income Loss From Discontinued Operations Net Of Tax Per Diluted Share IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare	-0.82
CY2022Q1	us-gaap	Income Loss From Discontinued Operations Net Of Tax Per Diluted Share IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare	-0.22
	us-gaap	Income Loss From Discontinued Operations Net Of Tax Per Diluted Share IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare	-0.98
	us-gaap	Income Loss From Discontinued Operations Net Of Tax Per Diluted Share IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare	-1.68
CY2023Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-1.33
CY2022Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.45
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-2.14
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-2.07
CY2023Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	30304000	shares
CY2022Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	29482000	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	29838000	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	29459000	shares
CY2023Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	30304000	shares
CY2022Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	29482000	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	29838000	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	29459000	shares
CY2023Q1	us-gaap	Other Comprehensive Income Loss Cash Flow Hedge Gain Loss After Reclassification Tax OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationTax	0	usd
CY2022Q1	us-gaap	Other Comprehensive Income Loss Cash Flow Hedge Gain Loss After Reclassification Tax OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationTax	-100000	usd
	us-gaap	Other Comprehensive Income Loss Cash Flow Hedge Gain Loss After Reclassification Tax OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationTax	-16000	usd
	us-gaap	Other Comprehensive Income Loss Cash Flow Hedge Gain Loss After Reclassification Tax OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationTax	-190000	usd
CY2023Q1	us-gaap	Other Comprehensive Income Loss Cash Flow Hedge Gain Loss After Reclassification And Tax OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax	0	usd
CY2022Q1	us-gaap	Other Comprehensive Income Loss Cash Flow Hedge Gain Loss After Reclassification And Tax OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax	104000	usd
	us-gaap	Other Comprehensive Income Loss Cash Flow Hedge Gain Loss After Reclassification And Tax OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax	586000	usd
	us-gaap	Other Comprehensive Income Loss Cash Flow Hedge Gain Loss After Reclassification And Tax OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax	646000	usd
CY2022Q1	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	104000	usd
	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	586000	usd
	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	646000	usd
CY2023Q1	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-40192000	usd
CY2022Q1	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-12982000	usd
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-63406000	usd
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-60470000	usd
CY2022Q2	us-gaap	Stockholders Equity StockholdersEquity	90697000	usd
CY2022Q3	us-gaap	Adjustments Related To Tax Withholding For Share Based Compensation AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation	67000	usd
CY2022Q3	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	785000	usd
CY2022Q3	us-gaap	Net Income Loss NetIncomeLoss	-11351000	usd
CY2022Q3	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	300000	usd
CY2022Q3	us-gaap	Stockholders Equity StockholdersEquity	80364000	usd
CY2022Q4	us-gaap	Adjustments Related To Tax Withholding For Share Based Compensation AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation	142000	usd
CY2022Q4	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	1108000	usd
CY2022Q4	us-gaap	Net Income Loss NetIncomeLoss	-12449000	usd
CY2022Q4	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	286000	usd
CY2022Q4	lfcr	Adjustment To Additional Paid In Capital Securities Purchase Agreement AdjustmentToAdditionalPaidInCapitalSecuritiesPurchaseAgreement	5000000	usd
CY2022Q4	us-gaap	Temporary Equity Shares Outstanding TemporaryEquitySharesOutstanding	0	shares
CY2022Q4	us-gaap	Temporary Equity Carrying Amount Including Portion Attributable To Noncontrolling Interests TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests	0	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	74167000	usd
CY2023Q1	lfcr	Temporary Equity Stock Issued During Period Shares New Issues TemporaryEquityStockIssuedDuringPeriodSharesNewIssues	39000	shares
CY2023Q1	us-gaap	Temporary Equity Stock Issued During Period Value New Issues TemporaryEquityStockIssuedDuringPeriodValueNewIssues	38082000	usd
CY2023Q1	us-gaap	Temporary Equity Accretion Of Dividends TemporaryEquityAccretionOfDividends	428000	usd
CY2023Q1	us-gaap	Dividends Preferred Stock Paidinkind DividendsPreferredStockPaidinkind	428000	usd
CY2023Q1	lfcr	Adjustment To Additional Paid In Capital Securities Purchase Agreement AdjustmentToAdditionalPaidInCapitalSecuritiesPurchaseAgreement	-178000	usd
CY2023Q1	us-gaap	Adjustments Related To Tax Withholding For Share Based Compensation AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation	65000	usd
CY2023Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	903000	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	-40192000	usd
CY2023Q1	us-gaap	Temporary Equity Shares Outstanding TemporaryEquitySharesOutstanding	39000	shares
CY2023Q1	us-gaap	Temporary Equity Carrying Amount Including Portion Attributable To Noncontrolling Interests TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests	38510000	usd
CY2023Q1	us-gaap	Stockholders Equity StockholdersEquity	34207000	usd
CY2021Q2	us-gaap	Stockholders Equity StockholdersEquity	202784000	usd
CY2021Q3	us-gaap	Adjustments Related To Tax Withholding For Share Based Compensation AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation	428000	usd
CY2021Q3	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	620000	usd
CY2021Q3	us-gaap	Net Income Loss NetIncomeLoss	-9509000	usd
CY2021Q3	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	366000	usd
CY2021Q3	us-gaap	Stockholders Equity StockholdersEquity	193833000	usd
CY2021Q4	us-gaap	Adjustments Related To Tax Withholding For Share Based Compensation AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation	84000	usd
CY2021Q4	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	686000	usd
CY2021Q4	us-gaap	Net Income Loss NetIncomeLoss	-38521000	usd
CY2021Q4	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	176000	usd
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	156090000	usd
CY2022Q1	us-gaap	Adjustments Related To Tax Withholding For Share Based Compensation AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation	6000	usd
CY2022Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	622000	usd
CY2022Q1	us-gaap	Net Income Loss NetIncomeLoss	-13086000	usd
CY2022Q1	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	104000	usd
CY2022Q1	us-gaap	Stockholders Equity StockholdersEquity	143724000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-63992000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-61116000	usd
	us-gaap	Goodwill And Intangible Asset Impairment GoodwillAndIntangibleAssetImpairment	300000	usd
	us-gaap	Goodwill And Intangible Asset Impairment GoodwillAndIntangibleAssetImpairment	32057000	usd
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	10392000	usd
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	14488000	usd
	us-gaap	Gain Loss On Sale Of Business GainLossOnSaleOfBusiness	2108000	usd
	us-gaap	Gain Loss On Sale Of Business GainLossOnSaleOfBusiness	0	usd
	us-gaap	Share Based Compensation ShareBasedCompensation	2796000	usd
	us-gaap	Share Based Compensation ShareBasedCompensation	1928000	usd
	us-gaap	Deferred Income Taxes And Tax Credits DeferredIncomeTaxesAndTaxCredits	57000	usd
	us-gaap	Deferred Income Taxes And Tax Credits DeferredIncomeTaxesAndTaxCredits	-5471000	usd
	us-gaap	Restructuring Costs And Asset Impairment Charges RestructuringCostsAndAssetImpairmentCharges	0	usd
	us-gaap	Restructuring Costs And Asset Impairment Charges RestructuringCostsAndAssetImpairmentCharges	5185000	usd
	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense	-101000	usd
	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense	540000	usd
	us-gaap	Increase Decrease In Receivables IncreaseDecreaseInReceivables	-8994000	usd
	us-gaap	Increase Decrease In Receivables IncreaseDecreaseInReceivables	7525000	usd
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	13451000	usd
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	11910000	usd
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	1169000	usd
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	1448000	usd
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	11405000	usd
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	13507000	usd
	us-gaap	Increase Decrease In Employee Related Liabilities IncreaseDecreaseInEmployeeRelatedLiabilities	-1895000	usd
	us-gaap	Increase Decrease In Employee Related Liabilities IncreaseDecreaseInEmployeeRelatedLiabilities	-2027000	usd
	us-gaap	Increase Decrease In Other Accrued Liabilities IncreaseDecreaseInOtherAccruedLiabilities	8570000	usd
	us-gaap	Increase Decrease In Other Accrued Liabilities IncreaseDecreaseInOtherAccruedLiabilities	-70000	usd
	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	1792000	usd
	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	662000	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-17169000	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-22045000	usd
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	12319000	usd
CY2022Q2	us-gaap	Deferred Finance Costs Noncurrent Net DeferredFinanceCostsNoncurrentNet	5500000	usd
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	18539000	usd
	lfcr	Business Sale Net Working Capital Adjustments BusinessSaleNetWorkingCapitalAdjustments	0	usd
	lfcr	Business Sale Net Working Capital Adjustments BusinessSaleNetWorkingCapitalAdjustments	2390000	usd
	us-gaap	Proceeds From Sale Of Equity Method Investments ProceedsFromSaleOfEquityMethodInvestments	0	usd
	us-gaap	Proceeds From Sale Of Equity Method Investments ProceedsFromSaleOfEquityMethodInvestments	45100000	usd
	us-gaap	Proceeds From Sale Of Property Plant And Equipment ProceedsFromSaleOfPropertyPlantAndEquipment	0	usd
	us-gaap	Proceeds From Sale Of Property Plant And Equipment ProceedsFromSaleOfPropertyPlantAndEquipment	1096000	usd
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	3347000	usd
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	98767000	usd
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	4822000	usd
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	0	usd
	us-gaap	Proceeds From Issuance Of Long Term Debt ProceedsFromIssuanceOfLongTermDebt	3367000	usd
	us-gaap	Proceeds From Issuance Of Long Term Debt ProceedsFromIssuanceOfLongTermDebt	0	usd
	us-gaap	Repayments Of Long Term Debt RepaymentsOfLongTermDebt	3199000	usd
	us-gaap	Repayments Of Long Term Debt RepaymentsOfLongTermDebt	86376000	usd
	us-gaap	Proceeds From Lines Of Credit ProceedsFromLinesOfCredit	18400000	usd
	us-gaap	Proceeds From Lines Of Credit ProceedsFromLinesOfCredit	45011000	usd
	us-gaap	Repayments Of Lines Of Credit RepaymentsOfLinesOfCredit	42400000	usd
	us-gaap	Repayments Of Lines Of Credit RepaymentsOfLinesOfCredit	34111000	usd
	us-gaap	Payments Related To Tax Withholding For Share Based Compensation PaymentsRelatedToTaxWithholdingForShareBasedCompensation	274000	usd
	us-gaap	Payments Related To Tax Withholding For Share Based Compensation PaymentsRelatedToTaxWithholdingForShareBasedCompensation	518000	usd
	us-gaap	Payments Of Debt Issuance Costs PaymentsOfDebtIssuanceCosts	3669000	usd
	us-gaap	Payments Of Debt Issuance Costs PaymentsOfDebtIssuanceCosts	169000	usd
	us-gaap	Proceeds From Issuance Of Preferred Stock And Preference Stock ProceedsFromIssuanceOfPreferredStockAndPreferenceStock	38082000	usd
	us-gaap	Proceeds From Issuance Of Preferred Stock And Preference Stock ProceedsFromIssuanceOfPreferredStockAndPreferenceStock	0	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	15129000	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-76163000	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	1307000	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	559000	usd
CY2022Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	1643000	usd
CY2021Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	1295000	usd
CY2023Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	2950000	usd
CY2022Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	1854000	usd
	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	3918000	usd
	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	1764000	usd
	us-gaap	Dividends Preferred Stock Paidinkind DividendsPreferredStockPaidinkind	428000	usd
	us-gaap	Dividends Preferred Stock Paidinkind DividendsPreferredStockPaidinkind	0	usd
CY2023Q1	lfcr	Number Of Product Category NumberOfProductCategory	2	product
	us-gaap	Fiscal Period FiscalPeriod	<div style="margin-top:10pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company’s fiscal year is the 52- or 53-week period that ends on the last Sunday of May with quarters within each year ending on the last Sunday of August, November, and February; however, in instances where the last Sunday would result in a quarter being 12-weeks in length, the Company’s policy is to extend that quarter to the following Sunday. A 14th week is included in the fiscal year every five or six years to realign the Company’s fiscal quarters with calendar quarters.</span></div><div style="margin-top:10pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The results of operations for the three and nine months ended February 26, 2023 are not necessarily indicative of the results that may be expected for an entire fiscal year because there is some seasonality in the order patterns of Lifecore’s customers which may lead to significant fluctuations in Lifecore Biomedical’s quarterly results of operations.</span></div>
	us-gaap	Use Of Estimates UseOfEstimates	<div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="margin-top:10pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of financial statements in conformity with GAAP requires management to make certain estimates and judgments that affect the amounts reported in the financial statements and accompanying notes. The accounting estimates that require management’s most significant and subjective judgments include revenue recognition; loss contingencies; sales returns and credit losses; recognition and measurement of current and deferred income tax assets and liabilities; the assessment of recoverability of long-lived and indefinite lived assets (including intangible assets and goodwill), and inventory; and the valuation and recognition of stock-based compensation.</span></div><div style="margin-top:10pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These estimates involve the consideration of complex factors and require management to make judgments. The analysis of historical and future trends can require extended periods of time to resolve and are subject to change from period to period. The actual results may differ from management’s estimates.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Going Concern Update</span></div><div style="margin-top:10pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As disclosed in the Company’s previous filings, the Company had previously determined that there were factors, which was principally the result of our noncompliance with financial covenants, that raised substantial doubt about its ability to continue as a going concern. Since that time, the Company has taken measures to strengthen its financial position, including the repayment and termination of the Prior Term Loan Facility, and the entry into the Refinancing Transactions (defined below), in each case, on May 22, 2023. The Refinancing Transactions provided the Company with additional liquidity, eliminated the Company’s noncompliance with its financial covenants under Credit Facilities (including granting the Company applicable waivers under the Revolving Term Loan Facility), reduced the Company’s near-term debt service costs, and eliminated certain financial covenants that existed under the Prior Term Loan Facility. In addition, the completion of the Company’s sale of the Yucatan and O Olive business, and the entry into an amended and restated supply agreement with Alcon Research, LLC (“Alcon”) to extend and expand its prior supply agreement, as further described in Note 10 – Subsequent Events, also provided the Company with additional liquidity. The cash provided under the Refinancing Transactions, completed divestitures of remaining Curation Foods businesses, and the lower debt service costs under our Refinancing Transactions provide improved forecasted cash flow from operations that allow sufficient liquidity over the next 12 months to meet our obligations as they come due.</span></div><div style="margin-top:10pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Based on the foregoing, management believes that our cash position as of the date of filing these financial statement (the “Filing Date”) and forecasted cash flow from operations is sufficient to meet capital and liquidity requirements for at least the next 12 months. As a result, there is no longer substantial doubt about the Company’s ability to continue as a going concern.</span></div>
CY2023Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	2950000	usd
CY2022Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	991000	usd
CY2022Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	1854000	usd
CY2021Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	1159000	usd
CY2023Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Disposal Group Including Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsDisposalGroupIncludingDiscontinuedOperations	0	usd
CY2022Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Disposal Group Including Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsDisposalGroupIncludingDiscontinuedOperations	652000	usd
CY2022Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Disposal Group Including Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsDisposalGroupIncludingDiscontinuedOperations	0	usd
CY2021Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Disposal Group Including Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsDisposalGroupIncludingDiscontinuedOperations	136000	usd
CY2023Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	2950000	usd
CY2022Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	1643000	usd
CY2022Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	1854000	usd
CY2021Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	1295000	usd
CY2023Q1	us-gaap	Inventory Finished Goods InventoryFinishedGoods	14636000	usd
CY2022Q2	us-gaap	Inventory Finished Goods InventoryFinishedGoods	13418000	usd
CY2023Q1	us-gaap	Inventory Raw Materials InventoryRawMaterials	22554000	usd
CY2022Q2	us-gaap	Inventory Raw Materials InventoryRawMaterials	21329000	usd
CY2023Q1	us-gaap	Inventory Work In Process InventoryWorkInProcess	11506000	usd
CY2022Q2	us-gaap	Inventory Work In Process InventoryWorkInProcess	9553000	usd
CY2023Q1	us-gaap	Inventory Net InventoryNet	48696000	usd
CY2022Q2	us-gaap	Inventory Net InventoryNet	44300000	usd
	us-gaap	Contract With Customer Liability Revenue Recognized ContractWithCustomerLiabilityRevenueRecognized	100000	usd
CY2022Q2	us-gaap	Allowance For Doubtful Accounts Receivable AllowanceForDoubtfulAccountsReceivable	5000	usd
	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	0	usd
	us-gaap	Allowance For Doubtful Accounts Receivable Write Offs AllowanceForDoubtfulAccountsReceivableWriteOffs	1000	usd
CY2023Q1	us-gaap	Allowance For Doubtful Accounts Receivable AllowanceForDoubtfulAccountsReceivable	4000	usd
CY2021Q2	us-gaap	Allowance For Doubtful Accounts Receivable AllowanceForDoubtfulAccountsReceivable	5000	usd
	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	0	usd
	us-gaap	Allowance For Doubtful Accounts Receivable Write Offs AllowanceForDoubtfulAccountsReceivableWriteOffs	0	usd
CY2022Q1	us-gaap	Allowance For Doubtful Accounts Receivable AllowanceForDoubtfulAccountsReceivable	5000	usd
CY2023Q1	us-gaap	Deferred Finance Costs Current Net DeferredFinanceCostsCurrentNet	8100000	usd
CY2023Q1	us-gaap	Contract With Customer Liability Revenue Recognized ContractWithCustomerLiabilityRevenueRecognized	500000	usd
CY2021Q1	us-gaap	Insurance Recoveries InsuranceRecoveries	1600000	usd
CY2023Q1	lfcr	Registration Rights Agreement Penalty RegistrationRightsAgreementPenalty	800000	usd
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	0	shares
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	743050	shares
CY2023Q1	us-gaap	Common Stock Capital Shares Reserved For Future Issuance CommonStockCapitalSharesReservedForFutureIssuance	3400000	shares
CY2023Q1	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	903000	usd
CY2022Q1	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	622000	usd
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	2796000	usd
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	1928000	usd
CY2010Q3	us-gaap	Stock Repurchase Program Authorized Amount1 StockRepurchaseProgramAuthorizedAmount1	10000000	usd
CY2023Q1	us-gaap	Stock Repurchase Program Authorized Amount1 StockRepurchaseProgramAuthorizedAmount1	3800000	usd
	us-gaap	Stock Repurchased During Period Shares StockRepurchasedDuringPeriodShares	0	shares
	us-gaap	Stock Repurchased During Period Shares StockRepurchasedDuringPeriodShares	0	shares
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	-40192000	usd
CY2022Q1	us-gaap	Net Income Loss NetIncomeLoss	-13086000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-63992000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-61116000	usd
CY2023Q1	us-gaap	Weighted Average Number Of Shares Issued Basic WeightedAverageNumberOfSharesIssuedBasic	30304000	shares
CY2022Q1	us-gaap	Weighted Average Number Of Shares Issued Basic WeightedAverageNumberOfSharesIssuedBasic	29482000	shares
	us-gaap	Weighted Average Number Of Shares Issued Basic WeightedAverageNumberOfSharesIssuedBasic	29838000	shares
	us-gaap	Weighted Average Number Of Shares Issued Basic WeightedAverageNumberOfSharesIssuedBasic	29459000	shares
CY2023Q1	us-gaap	Incremental Common Shares Attributable To Conversion Of Preferred Stock IncrementalCommonSharesAttributableToConversionOfPreferredStock	0	shares
CY2022Q1	us-gaap	Incremental Common Shares Attributable To Conversion Of Preferred Stock IncrementalCommonSharesAttributableToConversionOfPreferredStock	0	shares
	us-gaap	Incremental Common Shares Attributable To Conversion Of Preferred Stock IncrementalCommonSharesAttributableToConversionOfPreferredStock	0	shares
	us-gaap	Incremental Common Shares Attributable To Conversion Of Preferred Stock IncrementalCommonSharesAttributableToConversionOfPreferredStock	0	shares
CY2023Q1	us-gaap	Incremental Common Shares Attributable To Share Based Payment Arrangements IncrementalCommonSharesAttributableToShareBasedPaymentArrangements	0	shares
CY2022Q1	us-gaap	Incremental Common Shares Attributable To Share Based Payment Arrangements IncrementalCommonSharesAttributableToShareBasedPaymentArrangements	0	shares
	us-gaap	Incremental Common Shares Attributable To Share Based Payment Arrangements IncrementalCommonSharesAttributableToShareBasedPaymentArrangements	0	shares
	us-gaap	Incremental Common Shares Attributable To Share Based Payment Arrangements IncrementalCommonSharesAttributableToShareBasedPaymentArrangements	0	shares
CY2023Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	30304000	shares
CY2022Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	29482000	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	29838000	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	29459000	shares
CY2023Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-1.33
CY2022Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.45
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-2.14
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-2.07
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	78000	usd
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-5600000	usd
	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.002
	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.320
CY2023Q1	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	1000000	usd
CY2023Q1	us-gaap	Unrecognized Tax Benefits That Would Impact Effective Tax Rate UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate	900000	usd
CY2023Q1	us-gaap	Debt Instrument Carrying Amount DebtInstrumentCarryingAmount	107079000	usd
CY2022Q2	us-gaap	Debt Instrument Carrying Amount DebtInstrumentCarryingAmount	103712000	usd
CY2023Q1	us-gaap	Debt Instrument Carrying Amount DebtInstrumentCarryingAmount	107079000	usd
CY2022Q2	us-gaap	Debt Instrument Carrying Amount DebtInstrumentCarryingAmount	103712000	usd
CY2023Q1	us-gaap	Deferred Finance Costs Net DeferredFinanceCostsNet	8115000	usd
CY2022Q2	us-gaap	Deferred Finance Costs Net DeferredFinanceCostsNet	5534000	usd
CY2023Q1	us-gaap	Long Term Debt LongTermDebt	98964000	usd
CY2022Q2	us-gaap	Long Term Debt LongTermDebt	98178000	usd
CY2023Q1	us-gaap	Long Term Debt Current LongTermDebtCurrent	0	usd
CY2022Q2	us-gaap	Long Term Debt Current LongTermDebtCurrent	98178000	usd
CY2023Q1	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	98964000	usd
CY2022Q2	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	0	usd
	us-gaap	Number Of Operating Segments NumberOfOperatingSegments	3	segment
CY2023Q1	lfcr	Number Of Natural Food Brands NumberOfNaturalFoodBrands	3	brand
	us-gaap	Income Loss From Discontinued Operations Net Of Tax IncomeLossFromDiscontinuedOperationsNetOfTax	-29279000	usd
	us-gaap	Cost Of Goods And Services Sold Depreciation And Amortization CostOfGoodsAndServicesSoldDepreciationAndAmortization	8160000	usd
	us-gaap	Investment Income Dividend InvestmentIncomeDividend	0	usd
CY2023Q1	us-gaap	Revenue From Contract With Customer Including Assessed Tax RevenueFromContractWithCustomerIncludingAssessedTax	27600000	usd
CY2023Q1	us-gaap	Gross Profit GrossProfit	5978000	usd
CY2023Q1	us-gaap	Income Loss From Continuing Operations IncomeLossFromContinuingOperations	-15461000	usd
CY2023Q1	us-gaap	Income Loss From Discontinued Operations Net Of Tax IncomeLossFromDiscontinuedOperationsNetOfTax	-24731000	usd
CY2023Q1	us-gaap	Cost Of Goods And Services Sold Depreciation And Amortization CostOfGoodsAndServicesSoldDepreciationAndAmortization	2131000	usd
CY2023Q1	us-gaap	Investment Income Interest InvestmentIncomeInterest	22000	usd
CY2023Q1	us-gaap	Interest Expense InterestExpense	5818000	usd
CY2023Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	70000	usd
CY2023Q1	lfcr	Corporate Overhead Expense Benefit CorporateOverheadExpenseBenefit	0	usd
	us-gaap	Revenue From Contract With Customer Including Assessed Tax RevenueFromContractWithCustomerIncludingAssessedTax	77748000	usd
	us-gaap	Gross Profit GrossProfit	19570000	usd
	us-gaap	Income Loss From Continuing Operations IncomeLossFromContinuingOperations	-34713000	usd
	us-gaap	Investment Income Interest InvestmentIncomeInterest	53000	usd
	us-gaap	Interest Expense InterestExpense	13715000	usd
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	78000	usd
	lfcr	Corporate Overhead Expense Benefit CorporateOverheadExpenseBenefit	0	usd
CY2022Q1	us-gaap	Revenue From Contract With Customer Including Assessed Tax RevenueFromContractWithCustomerIncludingAssessedTax	37399000	usd
CY2022Q1	us-gaap	Gross Profit GrossProfit	12866000	usd
CY2022Q1	us-gaap	Income Loss From Continuing Operations IncomeLossFromContinuingOperations	-6638000	usd
CY2022Q1	us-gaap	Income Loss From Discontinued Operations Net Of Tax IncomeLossFromDiscontinuedOperationsNetOfTax	-6448000	usd
CY2022Q1	us-gaap	Cost Of Goods And Services Sold Depreciation And Amortization CostOfGoodsAndServicesSoldDepreciationAndAmortization	1996000	usd
CY2022Q1	us-gaap	Investment Income Interest InvestmentIncomeInterest	20000	usd
CY2022Q1	us-gaap	Interest Expense InterestExpense	4105000	usd
CY2022Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-87000	usd
CY2022Q1	lfcr	Corporate Overhead Expense Benefit CorporateOverheadExpenseBenefit	0	usd
	us-gaap	Revenue From Contract With Customer Including Assessed Tax RevenueFromContractWithCustomerIncludingAssessedTax	90140000	usd
	us-gaap	Gross Profit GrossProfit	31633000	usd
	us-gaap	Income Loss From Continuing Operations IncomeLossFromContinuingOperations	-11383000	usd
	us-gaap	Income Loss From Discontinued Operations Net Of Tax IncomeLossFromDiscontinuedOperationsNetOfTax	-49733000	usd
	us-gaap	Cost Of Goods And Services Sold Depreciation And Amortization CostOfGoodsAndServicesSoldDepreciationAndAmortization	5328000	usd
	us-gaap	Investment Income Interest InvestmentIncomeInterest	66000	usd
	us-gaap	Interest Expense InterestExpense	13877000	usd
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-5591000	usd
	lfcr	Corporate Overhead Expense Benefit CorporateOverheadExpenseBenefit	0	usd
CY2023Q1	us-gaap	Restructuring Costs RestructuringCosts	2741000	usd
	us-gaap	Restructuring Costs RestructuringCosts	4611000	usd
	us-gaap	Restructuring Costs RestructuringCosts	21389000	usd
CY2023Q1	us-gaap	Restructuring And Related Cost Expected Cost1 RestructuringAndRelatedCostExpectedCost1	23000000	usd

Files In Submission

Name	View Source	Status
FilingSummary.xml	Edgar Link	unprocessable
lfcr-20230226_def.xml	Edgar Link	unprocessable
0001005286-23-000095-index-headers.html	Edgar Link	pending
0001005286-23-000095-index.html	Edgar Link	pending
0001005286-23-000095.txt	Edgar Link	pending
0001005286-23-000095-xbrl.zip	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
lfcr-20230226.htm	Edgar Link	pending
lfcr-20230226.xsd	Edgar Link	pending
lfcr-20230226xexx311.htm	Edgar Link	pending
lfcr-20230226xexx312.htm	Edgar Link	pending
lfcr-20230226xexx321.htm	Edgar Link	pending
lfcr-20230226xexx322.htm	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
lfcr-20230226_cal.xml	Edgar Link	unprocessable
lfcr-20230226_lab.xml	Edgar Link	unprocessable
lfcr-20230226_pre.xml	Edgar Link	unprocessable
lfcr-20230226_htm.xml	Edgar Link	completed
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$LFCR
LIFECORE BIOMEDICAL, INC. \DE\ Stock $lfcr

2023 Q2 Form 10-Q Financial Statement

#000100528623000095 Filed on June 02, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$LFCR LIFECORE BIOMEDICAL, INC. \DE\ Stock $lfcr

2023 Q2 Form 10-Q Financial Statement

#000100528623000095 Filed on June 02, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$LFCR
LIFECORE BIOMEDICAL, INC. \DE\ Stock $lfcr